HPLC method for determination of SN-38 content and SN-38 entrapment efficiency in a novel liposome-based formulation, LE-SN38

被引:42
|
作者
Xuan, Tong
Zhang, J. Allen
Ahmad, Imran
机构
[1] Novartis Pharmaceut Corp, E Hanover, NJ 07936 USA
[2] Hospira Inc, Lake Forest, IL 60045 USA
[3] NeoPharma Inc, Waukegan, IL 60085 USA
关键词
HPLC; SN-38; liposomes; validation; entrapment efficiency;
D O I
10.1016/j.jpba.2005.10.051
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
A simple HPLC method was developed for quantification of SN-38, 7-ethyl-10-hydroxycamptothecin, in a novel liposome-based formulation (LE-SN38). The chromatographic separation was achieved on an Agilent Zorbax SB-C18 (4.6 mm x 250 mm, 5 mu m) analytical column using a mobile phase consisting of a mixture of NaH2PO4 (pH 3.1, 25 mM) and acetonitrile (50:50, v/v). SN-38 was detected at UV wavelength of 265 nm and quantitatively determined using an external calibration method. The limit of detection (LOD) and limit of quantitation (LOQ) were found to be 0.05 and 0.25 mu g/mL, respectively. The individual spike recovery of SN-38 ranged from 100 to 101%. The percent of relative standard deviation (%R.S.D.) of intra-day and inter-day analyses were less than 1.6%. The method validation results confirmed that the method is specific, linear, accurate, precise, robust and sensitive for its intended use. The current method was successfully applied to the determination of SN-38 content and drug entrapment efficiency in liposome-based formulation, LE-SN38 during early stage formulation development. (c) 2005 Elsevier B.V. All rights reserved.
引用
收藏
页码:582 / 588
页数:7
相关论文
共 50 条
  • [21] Population pharmacokinetics of CPT-11 and its metabolites SN-38 and SN-38 glucuronide in relation to diarrhea.
    Xie, R
    Mathijssen, RH
    Sparreboom, A
    Verweij, J
    Karlsson, MO
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2002, 71 (02) : P28 - P28
  • [22] Pharmacokinetic Assessment of Irinotecan, SN-38, and SN-38-Glucuronide: A Substudy of the FIRIS Study
    Satoh, Taroh
    Yasui, Hirofumi
    Muro, Kei
    Komatsu, Yoshito
    Sameshima, Shinichi
    Yamaguchi, Kensei
    Sugihara, Kenichi
    ANTICANCER RESEARCH, 2013, 33 (09) : 3845 - 3853
  • [23] Inhibition of SN-38 glucuronidation by ketoconazole.
    Yong, W
    Ramirez, J
    Innocenti, F
    Ratain, MJ
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2005, 77 (02) : P75 - P75
  • [24] Fecal SN-38 Content as a Surrogate Predictor of Intestinal SN-38 Exposure and Associated Irinotecan-induced Severe Delayed-Onset Diarrhea by a Novel Use of the Spectrofluorimetric Method
    Zheng, Zicong
    Saponjac, Vesna Tumbas
    Singh, Rashim
    Chen, Jie
    Srinual, Songpol
    Yin, Taijun
    Sun, Rongjin
    Hu, Ming
    PHARMACEUTICAL RESEARCH, 2024, 41 (09) : 1855 - 1867
  • [25] Fecal SN-38 Content as a Surrogate Predictor of Intestinal SN-38 Exposure and Associated Irinotecan-induced Severe Delayed-Onset Diarrhea by a Novel Use of the Spectrofluorimetric Method
    Zheng, Zicong
    Saponjac, Vesna Tumbas
    Singh, Rashim
    Chen, Jie
    Srinual, Songpol
    Yin, Taijun
    Sun, Rongjin
    Hu, Ming
    PHARMACEUTICAL RESEARCH, 2024, 41 (10) : 2075 - 2075
  • [26] Preclinical safety, pharmacokinetics and antitumor efficacy profile of liposome-entrapped SN-38 formulation
    Pal, A
    Khan, S
    Wang, YF
    Kamath, N
    Sarkar, AK
    Ahmad, A
    Sheikh, S
    Ali, S
    Carbonaro, D
    Zhang, A
    Ahmad, I
    ANTICANCER RESEARCH, 2005, 25 (1A) : 331 - 341
  • [27] pH-dependent association of SN-38 with lipid bilayers of a novel liposomal formulation
    Peikov, V
    Ugwu, S
    Parmar, M
    Zhang, A
    Ahmad, I
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2005, 299 (1-2) : 92 - 99
  • [28] PHARMACOKINETICS STUDY OF IRINOTECAN AND SN-38 BY COADMINISTERED THALIDOMIDE
    Shi, A. X.
    Hu, Y. L.
    Hu, X.
    Sun, C. H.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2009, 85 : S51 - S52
  • [29] In vitro conversion of irinotecan to SN-38 in human plasma
    Shingyoji, M
    Takiguchi, Y
    Watanabe-Uruma, R
    Asaka-Amano, Y
    Matsubara, H
    Kurosu, K
    Kasahara, Y
    Tanabe, N
    Tatsumi, K
    Kuriyama, T
    CANCER SCIENCE, 2004, 95 (06): : 537 - 540
  • [30] Inhibition of SN-38 glucuronidation by gefitinib and its metabolite
    Wei Li
    Yafei Xing
    Yong Liu
    Cancer Chemotherapy and Pharmacology, 2015, 75 : 1253 - 1260